| Code | CSB-RA011662MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to SSGJ-610, targeting interleukin-5 (IL-5), a key cytokine in the regulation of eosinophil biology. IL-5 is primarily produced by T helper 2 (Th2) cells, mast cells, and innate lymphoid cells, playing a critical role in eosinophil differentiation, activation, survival, and recruitment to sites of inflammation. Elevated IL-5 levels are strongly associated with eosinophilic disorders, including severe asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and allergic diseases. By binding to IL-5, this antibody prevents interaction with its receptor on eosinophils, thereby inhibiting eosinophil-mediated inflammatory responses.
SSGJ-610 is a preclinical/early clinical stage biosimilar drug of anti-IL-5 monoclonal antibody. It binds to and neutralizes IL-5 with high affinity, blocking its binding to the surface receptors of eosinophils, thereby inhibiting the activation, proliferation and survival of eosinophils and alleviating the inflammation driven by them. This biosimilar provides researchers with a valuable tool for investigating eosinophil biology, inflammatory mechanisms in allergic and autoimmune conditions, and the therapeutic potential of IL-5 neutralization. It supports studies in immunology, respiratory disease research, and the development of targeted interventions for eosinophil-associated pathologies.
There are currently no reviews for this product.